NEW YORK (TheStreet) -- RATINGS CHANGES

BioTelemetry(BEAT) - Get Report was upgraded to hold at TheStreet Ratings.

General Cable (BGC) was downgraded at DA Davidson to neutral from buy. Twelve-month price target is $28. Estimates were also cut, given the company's new guidance, DA Davidson said.

Cullen/Frost(CFR) - Get Report was upgraded at Sterne Agee to neutral from underperform. Valuation call, based on a 12-month price target of $74, Sterne Agee said.

3D Systems(DDD) - Get Report was initiated at UBS with a neutral rating. Company has broad product line and acquisition strategy, but bumpy near-term financials, UBS said. Twelve-month price target is $62.

[Read: Microsoft Hits 52-Week High, Set to Crush $50]

Genie Energy(GNE) - Get Report was initiated with a hold rating at TheStreet Ratings.

Invensense (INVN) was downgraded at Oppenheimer to perform from outperform. Company could face increased competition, Oppenheimer said.

Laboratory Corporation of America(LH) - Get Report was upgraded at UBS to neutral from buy. Driven by lab industry's successful efforts to push off Medicare CLFS changes until 2017, UBS said. Twelve-month price target is $112.

Mednax(MD) - Get Report was upgraded at Deutsche Bank to buy from hold. Twelve-month price target is $73. Company can deliver higher organic growth, Deutsche Bank said.

[Read: Earnings Preview: Investing Ahead of Earnings: CarMax, Monsanto, Micron and Texas Industries]

Nvidia(NVDA) - Get Report was upgraded at JMP Securities to outperform from market perform. Twelve-month price target is $26. Company is focused on increasing gross margin, JMP said.

Stratasys(SSYS) - Get Report was initiated at UBS with a buy rating. Better execution and narrower focus compared to comparables, UBS said. Twelve-month price target is $125.

United Continental(UAL) - Get Report was upgraded at UBS to buy from neutral. Unit revenue growth set to accelerate, UBS said. Twelve-month price target is $50. Buy rating.

[Read: Colorado's Attorney General Still Says Legalized Pot Is Bad Public Policy]

Waddell & Reed(WDR) - Get Report was upgraded at Goldman Sachs to buy from neutral. Twelve-month price target is $84. Company's consistency and growth are underappreciated by the market, Goldman said.

Stock Comments / EPS Changes

General Motors(GM) - Get Report 12-month price target was cut at UBS. Lingering recall cost is rising, UBS said. Twelve-month price target is $49. Buy rating.

MetLife(MET) - Get Report was added to the US 1 List at Bank of America/Merrill Lynch. Twelve-month price target is $67. Company is a top franchise, but trades at a discount to its peers, Bank of America/Merrill Lynch said.

Follow TheStreet on Twitter and become a fan on Facebook

This article was written by a staff member of TheStreet.